BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

XTL Biopharmaceuticals Ltd. (XTLB) Files Application for Listing on the NASDAQ


6/5/2012 10:19:39 AM

HERZLIYA, Israel, June 4, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it has filed an application for relisting its ADRs on the NASDAQ Stock Exchange. The Company and its advisors believe it currently is in compliance with the criteria for the NASDAQ listing (subject to additional qualitative criteria of the Listing Qualifications Committee), except for satisfying the minimum bid ADR price, which will be adjusted if required, by changing the ADR ratio.

Currently, in addition to the trading on the Tel Aviv Stock Exchange, the ADRs of the Company are quoted over-the-counter in the US. In addition, the Company is registered with the Securities and Exchange Commission and reports according to its legal obligations.

David Grossman, XTL's CEO, commented: "Our relisting on NASDAQ will allow greater visibility within the US institutional investment community together with the leading biotechnology companies."

Ronen Twito, Deputy CEO and CFO, mentioned: "The NASDAQ listing will reflect the progress of the Company on the business as well as financial aspects and will create new opportunities for the Company and its shareholders."

About XTL Biopharmaceuticals, Ltd. ("XTL")

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

XTL's lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the FDA. rHuEPO, has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia.

XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).

Contact: Investor Relations, XTL Biopharmaceuticals Ltd., Tel: +972-9-955-7080, Email: ir@xtlbio.com

SOURCE XTL Biopharmaceuticals Ltd



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES